BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 27678173)

  • 1. Recent Trends in Nanotechnology Toward CNS Diseases: Lipid-Based Nanoparticles and Exosomes for Targeted Therapeutic Delivery.
    Cardoso AM; Guedes JR; Cardoso AL; Morais C; Cunha P; Viegas AT; Costa R; Jurado A; Pedroso de Lima MC
    Int Rev Neurobiol; 2016; 130():1-40. PubMed ID: 27678173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnological advances for the delivery of CNS therapeutics.
    Wong HL; Wu XY; Bendayan R
    Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
    Sa P; Singh P; Dilnawaz F; Sahoo SK
    Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of nanotechnology in drug delivery to the central nervous system.
    Saeedi M; Eslamifar M; Khezri K; Dizaj SM
    Biomed Pharmacother; 2019 Mar; 111():666-675. PubMed ID: 30611991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for transporting nanoparticles across the blood-brain barrier.
    Zhang TT; Li W; Meng G; Wang P; Liao W
    Biomater Sci; 2016 Feb; 4(2):219-29. PubMed ID: 26646694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Gene Therapy Towards Treating Neurodegenerative Disea ses Employing Polymeric Nanosystems.
    Bangde P; Atale S; Dey A; Pandit A; Dandekar P; Jain R
    Curr Gene Ther; 2017; 17(2):170-183. PubMed ID: 28494742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
    Teixeira MI; Lopes CM; Amaral MH; Costa PC
    Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.
    Meng J; Agrahari V; Youm I
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):84-98. PubMed ID: 27449494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanobiotechnology-based drug delivery in brain targeting.
    Dinda SC; Pattnaik G
    Curr Pharm Biotechnol; 2013; 14(15):1264-74. PubMed ID: 24910011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic approaches of magnetic nanoparticles for the central nervous system.
    Dilnawaz F; Sahoo SK
    Drug Discov Today; 2015 Oct; 20(10):1256-64. PubMed ID: 26103617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS.
    Peluffo H; Unzueta U; Negro-Demontel ML; Xu Z; Váquez E; Ferrer-Miralles N; Villaverde A
    Biotechnol Adv; 2015; 33(2):277-87. PubMed ID: 25698504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of Nanomedicine to the CNS Diseases.
    Carradori D; Gaudin A; Brambilla D; Andrieux K
    Int Rev Neurobiol; 2016; 130():73-113. PubMed ID: 27678175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymeric nanoparticles - targeted drug delivery systems for treatment of CNS disorders and their possible endocrine disrupting activities.
    Rollerova E; Scsukova S; Jurcovicova J; Mlynarcikova A; Szabova E; Kovriznych J; Zeljenkova D
    Endocr Regul; 2011 Jan; 45(1):49-60. PubMed ID: 21314211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders.
    Alajangi HK; Kaur M; Sharma A; Rana S; Thakur S; Chatterjee M; Singla N; Jaiswal PK; Singh G; Barnwal RP
    Mol Brain; 2022 Jun; 15(1):49. PubMed ID: 35650613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-based nanocarriers for CNS-targeted drug delivery.
    Micheli MR; Bova R; Magini A; Polidoro M; Emiliani C
    Recent Pat CNS Drug Discov; 2012 Apr; 7(1):71-86. PubMed ID: 22283231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances.
    Goyal K; Koul V; Singh Y; Anand A
    Cent Nerv Syst Agents Med Chem; 2014; 14(1):43-59. PubMed ID: 25360772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodegradable Nanoparticles for Delivery of Therapeutics in CNS Infection.
    DeMarino C; Schwab A; Pleet M; Mathiesen A; Friedman J; El-Hage N; Kashanchi F
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):31-50. PubMed ID: 27372507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective drug delivery approaches to lesioned brain through blood brain barrier disruption.
    Al-Ahmady ZS
    Expert Opin Drug Deliv; 2018 Apr; 15(4):335-349. PubMed ID: 29466890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the treatment of neurodegenerative disorders employing nanoparticles.
    Spuch C; Saida O; Navarro C
    Recent Pat Drug Deliv Formul; 2012 Apr; 6(1):2-18. PubMed ID: 22272933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendrimer advances for the central nervous system delivery of therapeutics.
    Xu L; Zhang H; Wu Y
    ACS Chem Neurosci; 2014 Jan; 5(1):2-13. PubMed ID: 24274162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.